Oculis Holding AG
SWB:CR5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Oculis Holding AG (CR5) under the Base Case is 1.38 EUR per share. Compared with the current market price of 6.66 EUR, the stock appears Overvalued by 79% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Oculis Does
Oculis Holding AG is a biopharmaceutical company focused on eye and vision diseases. It develops medicines for conditions that damage the retina, the surface of the eye, and the optic nerve, aiming to deliver treatments that can be used more easily than traditional eye drugs. Its work is centered on clinical-stage drug development rather than running a broad commercial product business.
- Headquarters
- Switzerland CH
- Employees
- 60
- IPO date
- Mar 3, 2023
Earnings Waterfall
Oculis Holding AG
What is the Intrinsic Value of one CR5 stock?
The intrinsic value for Oculis Holding AG (CR5) under the Base Case is 1.38 EUR.
Is CR5 stock undervalued or overvalued?
Compared with the current market price of 6.66 EUR, the stock appears Overvalued by 79% .